Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Eskandari-Nasab, Ebrahima; b | Hashemi, Mohammadb; * | Ebrahimi, Mahboubehb | Amininia, Shadib | Bahari, Gholamrezab | Mashhadi, Mohammad-Alic | Taheri, Mohsend
Affiliations: [a] Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran | [b] Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran | [c] Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran | [d] Department of Genetics, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Correspondence: [*] Corresponding author: Mohammad Hashemi, Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Tel.: +98 541 3235122; E-mail: mhd.hashemi@gmail.com.
Abstract: Background:Recent evidence has demonstrated the implication of CC chemokine ligand 5 (CCL5) and CC chemokine receptor 5 (CCR5) in breast tumor initiation and progression. Objective:The purpose of this study was to investigate whether single nucleotide polymorphisms of CCL5 -403 G>A (rs2107538) and CCR5 Δ32 genes are associated with the breast cancer (BC) risk. Methods:A total of 439 subjects including on 236 BC patients and 203 healthy controls from the same area were recruited. The CCL5 -403 G>A and CCR5 Δ32 polymorphisms were genotyped by allele-specific polymerase chain reaction (AS-PCR) and PCR, respectively. Results:Our data demonstrated that the CCL5 -403 GA and GA+AA genotypes, with a higher frequency in the BC patients compared to the control group, were associated with an increased risk of BC in the codominant (GG vs. GA OR=1.75, 95%CI=1.07–2.86, P=0.025) and dominant models (GG vs. GA+AA: OR=1.84, 95%CI=1.15–2.93, P=0.014), respectively. Additionally, the A allele of CCL5 -403 G>A variation was found more prevalent in the BC patients than in controls (14% vs. 8%) and was a risk factor for BC (G vs. A: OR=1.87, 95% CI=1.21–2.89, P=0.004). Conclusions:Our findings highlighted that the CCL5 -403 G>A polymorphism is a risk factor for BC in our population. Our findings suggest that the CCL5 -403 GA and GA+AA genotypes and the A allele were associated with an elevated risk of BC which may function as risk factor for breast carcinoma.
Keywords: CCL5, CCR5, breast cancer, gene polymorphism
DOI: 10.3233/CBM-140411
Journal: Cancer Biomarkers, vol. 14, no. 5, pp. 343-351, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl